Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)

[1]  James M. Wilson,et al.  ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  D. Goldstein,et al.  Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Abrams,et al.  Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial , 2013, The Lancet. Oncology.

[4]  Daniel Normolle,et al.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. , 2012, International journal of radiation oncology, biology, physics.

[5]  Radiation dose ≥54 Gy and CA 19–9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation , 2012, Radiation oncology.

[6]  Jeffrey E. Lee,et al.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[8]  J. Tepper,et al.  Radiosensitization of Epidermal Growth Factor Receptor/HER2–Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status , 2010, Clinical Cancer Research.

[9]  T. Briere,et al.  Dose escalation with proton or photon radiation treatment for pancreatic cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  R. Muschel,et al.  Tumor vascular changes mediated by inhibition of oncogenic signaling. , 2009, Cancer research.

[11]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Chauffert,et al.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  K. Cengel,et al.  Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. , 2008, Cancer research.

[14]  W. Hohenberger,et al.  Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Ian Frank,et al.  Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans , 2008, Cancer biology & therapy.

[16]  Jeffrey S Barrett,et al.  Shortening the timeline of pediatric phase I trials: the rolling six design. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Edgar Ben-Josef,et al.  Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. , 2007, International journal of radiation oncology, biology, physics.

[18]  J. Quivey,et al.  A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. , 2007, International journal of radiation oncology, biology, physics.

[19]  S. Hahn,et al.  Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. , 2006, Cancer research.

[20]  Rosemarie Mick,et al.  HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. , 2005, Cancer research.

[21]  G. Monges,et al.  Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. , 2004, International journal of radiation oncology, biology, physics.

[22]  Jay Burmeister,et al.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. , 2004, International journal of radiation oncology, biology, physics.

[23]  J. Roeske,et al.  Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. , 2004, International journal of radiation oncology, biology, physics.

[24]  Frank Pajonk,et al.  The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. , 2002, Cancer research.